-+ 0.00%
-+ 0.00%
-+ 0.00%

Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26

Benzinga·05/19/2026 12:03:58
Listen to the news
Oral Presentation details
Title: Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154
Presenter: Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine
Session: Pharmaceutical Pipeline (Oral Presentation)
Date: Tuesday, May 26, 2026
Time: 3:20 PM ET
Location: Loews Miami Beach Hotel, Miami, FL

The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).

Poster Presentation
Date: Wednesday, May 27, 2026
Time: 11:45 AM – 1:30 PM ET
Session: Poster Session 1, Pharmaceutical Pipeline
Poster number: W98